Clinical trial · Interventional
Avastin and Taxotere for Esophagogastric Cancer
Phase II Study of Bevacizumab and Docetaxel (AvaTax) in Metastatic Esophagogastric Cancer
NCT00137813CI-TRIAL-00035590completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine what effects (good and bad) bevacizumab (Avastin) and docetaxel (Taxotere), used in combination, have on metastatic gastric and esophageal cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Docetaxel | Drug | Docetaxel | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate the overall response and safety of the combination docetaxel and bevacizumab in patients with esophageal or gastric cancer
- timeFrame
- 3 years
Secondary outcomes (1)
- measure
- To evaluate the duration of response, progression-free and overall survival of patients with esophageal or gastric cancer treated with docetaxel and bevacizumab
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed, unresectable or metastatic stage IV esophageal or gastric carcinoma * Measurable disease greater than or equal to 1cm by spiral computed tomography (CT) scan or greater than or equal to 2cm by other radiographic technique * ECOG performance status 0-2 * One prior chemotherapy for metastatic disease permitted * White blood cell count greater than or equal to 3,000/mm * Absolute neutrophil count greater than or equal to 1,500/mm3 * Platelet count greater than or equal to 100,000/mm3 * Hemoglobin greater than or equal to 8.0g/dl * Creatinine less than 2.0mg/dL * Total bilirubin less than 1.9mg/dL Exclusion Criteria: * Pregnant or lactating women * History or evidence of central nervous system (CNS) disease * Other active malignancies other than non-melanoma skin cancer or in-situ cervical cancer * History of severe hypersensitivity to docetaxel, bevacizumab or drugs formulated with polysorbate 80. * Current, recent or planned treatment with standard chemotherapy, radiation therapy or another experimental therapy. * History of other disease or metabolic dysfunction. * Serious, non-healing wound, ulcer, or bone fracture.
References
Publications (0)
Data not yet available
No reference posted for this study.